Scientific publications	»
Media	»
History	»
Who Is Who?	»
Press releases	»
Campaign	»
Downloads	»

The Hungarian invention has opened a new chapter in cancer treatment and patients were given new hope.

In 2003, the opinion leader British Journal of Cancer published the outstanding results of clinical research relating to Avemar. The most interesting results published in the journal, which many consider to be the leading formulator of opinion concerning cancer therapy, are often at the centre of international press attention. The report given by the American CNN television news network is a shining example of the attention paid the subject by the international press.

The anticancer product featured in a report by the American television network CNN is already available in many countries. According to experts, the product, which is used in cancer therapy, can prove to be a new weapon in the fight against cancer, as, when administered in combination with traditional oncological therapies (surgery, chemotherapy and radiation therapy), it improves the quality of life of patients suffering from malignant tumours and prolongs survival time. This potential is further strengthened by the fact that the product is based on natural ingredients which have no side effects and can be easily administered. In Hungary, where the product was conceived, the mortality rate of cancer, which had been on the rise for decades, began declining after its introduction and in the wake of its increasingly wide-spread use. Such mortality rate continue to rise in all Hungary's neighboring countries. Researchers and oncologists from points all around the globe, including UCLA (University of California at Los Angeles), the Universities of Sheffield and Barcelona, Israeli clinics, the University of Tel Aviv, the Blokhin Oncological Centre in Moscow and the University of Genoa - some 20 countries in all - joined in the research.

Reminder: The Hungarian medical authorities also registered Avemar as medical nutriment for cancer patients on 1 July 2002 with the following approved label: 'Indications: Avemar is recommended for use by patients suffering from cancer as a supplement to clinical oncological treatments (surgery, radiotherapy, chemotherapy, immunotherapy, etc.' These results are the fruit of many years' work by research groups in Britain, the United States, Israel, Spain, Italy, Russia and, last but not least, Hungary. The credibility of their claims is assured by the numerous publications concerning the product which have appeared in international journals.

After Avemar's registration in 2002, it was not long before the Czech medical authorities also registered it as a medical nutriment for cancer patients. Soon after this, the Bulgarian authorities also registered and approved Avemar as a medical nutriment for cancer patients. In Australia, the product falls into the category of therapeutic products for use in immunomodulant therapy, while, in Austria, it is already paid for entirely by the National Health service.

In 2002, the American CNN television news network made its first report about the results of the Avemar Program under the heading 'Cancer research in Hungary has reached a turning point.'

Also in 2002, American and Spanish researchers published a large-scale article in the Journal of Biological Chemistry, the authoritative journal for molecular biology, in which they exposed the causes behind one of the key factors contributing to Avemar's effect mechanism. As they explained it, Avemar has a direct influence on the metabolism of tumour cells which prevents the cancer cells from reproducing themselves and from carrying out the all-important DNA synthesis. As a result, the tumour does not develop further and the cancer cells, owing to Avemar's effect in other areas, die off, either on their own or under the influence of the body's cancer-killing mechanisms.

In 2003, the oppinion leader British Journal of Cancer (the official oncological journal in Britain and one of the authorities on clinical oncology) published the outstanding results of clinical research relating to Avemar. This was the first article concerning the results of clinical tests undertaken in Hungary by Hungarians published in the journal since its foundation. The most interesting results published in the journal, which many consider to be the leading formulator of opinion concerning cancer therapy, are often at the centre of international press attention.

The doctors performing the research gave an account of the newest results at the symposium organised as part of the Hungarian Oncological Society's 25th jubilee congress in November 2003, referring back to their first communication five years previously. At the press conference held at the congress, both the Society's president and secretary confirmed before journalists that Avemar's efficacy has been proven. This fact is further supported by the test carried out in Moscow by Russian researchers on advanced-stage melanoma patients. The test demonstrated that, among patients with melanoma, those who took Avemar had a significantly longer progression- and metastasis-free survival period than those in the control group.

The report given by the American CNN television news network is a shining example of the attention paid the subject by the international press.
In the report, Prof. Ferenc Jakab, the department director and chief physician at the Uzsoki Street Hospital in Budapest, discussing a test performed at the hospital, again emphasised that significant differences can be observed in patients undergoing treatment which includes Avemar when compared with those who do not receive Avemar.
(176 patients suffering from colorectal cancer took part in the test, most of which were at stages 3 and 4. The average follow-up period was 18.3 months. At the beginning of the test, the global prognosis for the Avemar group was significantly worse than that for the control group. The conclusions of the test were that, when combined with surgery, radio- or chemotherapy, Avemar was able to reduce significantly the formation of metastases and lengthen survival time in colorectal cancer patients.) Prof. Miklós Kásler, director general of the National Oncological Institute, said, "It is not a dietary supplement, but it is a very important new treatment, registered for cancer treatment." The success of Avemar in Hungarian scientific circles can also be measured in the number of research and development applications. Zoltán Somogyi, department director at the National Office of Research and Technology, explained that "Avemar is a positive example of how an original Hungarian idea can develop into a ready-to-market product - through steady innovative activities". Lastly, Ákos Resetár, leader of the group of companies coordinating the Avemar Program's research activities, told the television news channel about the philosophy behind the research.

In Europe (including in Hungary), Avemar is currently the only non-prescription product with an officially approved label available on the market specifically for cancer patients. Avemar is the first product developed by Hungarians with both recommended and recognised oncological indications to have been registered in Hungary for several decades. The Avemar Program's newest challenge is to find a way to get rid of the product's unpleasant taste, explore its active ingredients and map out new indications. There are already reassuring signs concerning the first of these goals, and it is planned that, by the autumn, new technological advances will make it possible to do away with Avemar's unpleasant taste. Research into its active ingredients is already underway. The mapping out of new indications already arose at the beginning of research, and the results are currently awaiting summarising and assessment, while scientific articles concerning these results are currently forthcoming and will be presented in November 2004 at the International Autoimmune Congress in Budapest, in which more than 1000 people will participate.

Home